The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients.
Mariana Reza
No relevant relationships to disclose
Anders Bjartell
Consultant or Advisory Role - EXINI Diagnostics
Honoraria - EXINI Diagnostics
Mattias Ohlsson
Employment or Leadership Position - EXINI Diagnostics
Stock Ownership - EXINI Diagnostics
Lars Edenbrandt
Employment or Leadership Position - EXINI Diagnostics
Stock Ownership - EXINI Diagnostics
Elin Tragardh
No relevant relationships to disclose